Board of Directors

About AntriaBio

Board of Directors

Nevan Charles Elam, J.D.

Chairman and CEO

Mr. Elam co-founded AntriaBio in October 2012 with Dr. Huh and Dr. Mantripragada, and brings to the company a rich background in management, operations, consulting, finance, and corporate law. He currently serves on the board of directors of Savara Pharmaceuticals in Austin, Texas as well as Aerogen, Inc. in Galway, Ireland.

Mr. Elam was previously CEO of AeroSurgical Limited, a European medical device company, and prior to that, had a very successful career at Nektar Therapeutics (NASDAQ: NKTR). He served as SVP and Head of the Pulmonary Business Unit where he managed a team of over 600 professionals and various partnerships with large pharmaceutical companies. He successfully worked with members of his scientific team at Nektar to spin out Pearl Therapeutics to focus on treatments for asthma and COPD (in 2013 Pearl Therapeutics was acquired by AstraZeneca for $1 billion). In 2008, he negotiated the sale of the pulmonary business unit at Nektar to Novartis for $200 million enterprise value.

Prior to his role at Nektar, Mr. Elam was CFO and co-founder of E2open, (NASDAQ: EOPN), an IT platform company serving the electronics and healthcare industries where, in addition to managing finance and corporate and business development, he established operations in five locations in Asia including Singapore, Kuala Lumpur, Taipei, Tokyo, and Seoul.

In the 1990s, Mr. Elam had a successful career at the venerable law firm of Wilson Sonsini Goodrich & Rosati in Palo Alto, California where he was a partner in the corporate practice. He worked with companies in a variety of industries including healthcare, where his clients ranged from large biotech organizations such as Genentech to small novel therapeutic companies in the US and Europe. Mr. Elam advised clients on a range of matters including debt and equity financings, FDA issues, acquisitions, partnerships and cross-border transactions. He also served clients such as Hewlett Packard and Sun Microsystems and notably, in 1997 he negotiated the sale of Steve Jobs' company, Next, to Apple.

Mr. Elam received his B.A. from Howard University and his J.D. from Harvard Law School.

Hoyoung Huh, M.D., Ph.D.

Chairman of Scientific Advisory Board & Business Development

In addition to his role at AntriaBio, Dr. Hoyoung Huh currently serves as the Chairman of Geron Corporation (NASDAQ: GERN) and Chairman of CytomX Therapeutics.  Dr. Huh has been involved in the formation, management and financing of more than 20 successful entities across the United States, Europe and Asia. He was previously President & CEO of BiPar Sciences, which was acquired by Sanofi-Aventis for $500 million in 2009. He also served as the Chairman of Epizyme (NASDAQ:EPZM), Chief Operating Officer and board member of Nektar Therapeutics (NASDAQ:NKTR), board member of EOS which was acquired by Clovis Oncology in 2013, board member of Calibra Medical which was acquired by J&J in 2012, and board member of Facet Biotech (NASDAQ:FACT) which was acquired by Abbott Laboratories for $722 million in 2010. Dr. Huh was formerly a partner at McKinsey & Company in the healthcare and technology practices. Dr. Huh holds a B.S. in Biochemistry from Dartmouth College, an M.D. from Cornell University Medical College, and a Ph.D. in Cell biology & Genetics from Cornell University/Sloan-Kettering Institute.

Barry Sherman, M.D.


Dr. Sherman joined AntriaBio's Board in July 2014 and was most recently President and CEO of StemPar Sciences, a newly formed company in the emerging field of cancer metabolism. He has more than 30 years of experience in academic and pharmaceutical biomedical research. Dr. Sherman was Genentech's first Senior Vice President and Chief Medical Officer, served as President and CEO of Anergen Inc., and was a founder of Pain Therapeutics and BiPar Sciences. Prior to joining Genentech in 1985, Dr. Sherman was Professor of Medicine and Endocrinology at the University of Iowa-College of Medicine, where he served as Associate Chairman of the Department of Internal Medicine and Director of the National Institutes of Health-Sponsored Clinical Research Center. Dr. Sherman is a graduate of the University of Michigan where he received both his A.B. and M.D. degrees with honors.

David F. Welch, Ph.D.


Dr. Welch joined AntriaBio's Board in June 2015. He currently serves as President and Co-Founder of Infinera Corporation (NASDAQ:INFN). Dr. Welch is both an experienced entrepreneur and scientist with extensive expertise in building successful companies based on disruptive technologies. Most recently as the Co-Founder of Infinera Corporation, Dr. Welch pioneered photonic integrated circuit technology, which has transformed the field of optical telecommunication networks. His track record for creating shareholder value by leveraging advanced technologies into high-growth and highly profitable businesses is well established with both Infinera Corporation and SDL Inc., where he was Chief Technology Officer and Vice President of Corporate Development. Dr. Welch holds a B.S. in Electrical Engineering from the University of Delaware and a Ph.D. in Electrical Engineering from Cornell University. Dr. Welch is also the founder of Students Matter, a non-profit organization focused on i mproving public education by protecting the rights of students to equal access to quality education.

Tae Hoon Kim


Mr. Kim brings to the Board a wealth of experience from his time at Genentech, Inc. and most recently as Chief Operating Officer at Aju Pharm, a pharmaceutical company in the Republic of Korea with more than 60 years of operations and over 220 manufactured products in the pharmaceutical, medical device and consumer health businesses. Mr. Kim holds a B.S. in Cellular & Molecular Biology from the University of Michigan and an M.B.A. from Tuck School of Business at Dartmouth College.

Samir R. Patel, M.D.


Dr. Patel is co-founder, principal and former CEO of SPEC Pharma, LLC, which specializes in injectable therapies with complex manufacturing. He is also co-founder, principal and CEO of Digital Therapeutics, LLC, a company investigating therapies for digital ulcerations, a severe rheumatologic condition with high unmet medical need. Dr. Patel previously served as Medical Director of Centocor, Inc., a Johnson & Johnson Company, where he oversaw Medical Affairs for Remicade, Stelara and Simponi. Prior to joining Centocor, he practiced adult and pediatric rheumatology in Austin, Texas. Dr. Patel holds a B.S. in Biology from the University of Cincinnati and an M.D. from the Medical College of Ohio. He completed his residency in Internal Medicine and fellowship in Rheumatology at the University of New Mexico.